Net Income (Loss) Attributable to Parent in USD of ESSA Pharma Inc. from 2019 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ESSA Pharma Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to Q2 2025.
  • ESSA Pharma Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$4M, a 44.7% increase year-over-year.
  • ESSA Pharma Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$25.3M, a 8.69% increase year-over-year.
  • ESSA Pharma Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$28.5M, a 7.38% decline from 2023.
  • ESSA Pharma Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$26.6M, a 24.3% increase from 2022.
  • ESSA Pharma Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$35.1M, a 4.63% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

ESSA Pharma Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 -$25.3M -$4M +$3.23M +44.7% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 -$28.5M -$6.37M +$2.61M +29.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 -$31.1M -$8.53M -$2.57M -43% Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-11
Q3 2024 -$28.5M -$6.36M -$874K -15.9% Jul 1, 2024 Sep 30, 2024 10-K 2024-12-17
Q2 2024 -$27.7M -$7.23M +$65.1K +0.89% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 -$27.7M -$8.99M -$1.93M -27.3% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 -$25.8M -$5.96M +$778K +11.5% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-11
Q3 2023 -$26.6M -$5.48M +$843K +13.3% Jul 1, 2023 Sep 30, 2023 10-K 2024-12-17
Q2 2023 -$27.4M -$7.3M +$1.53M +17.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$29M -$7.06M +$3.79M +35% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$32.7M -$6.74M +$2.36M +25.9% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-13
Q3 2022 -$35.1M -$6.32M +$2.24M +26.1% Jul 1, 2022 Sep 30, 2022 10-K 2023-12-12
Q2 2022 -$37.3M -$8.83M -$74.7K -0.85% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$37.3M -$10.9M +$2.11M +16.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$39.4M -$9.1M -$2.57M -39.4% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-07
Q3 2021 -$36.8M -$8.56M -$4.01M -88% Jul 1, 2021 Sep 30, 2021 10-K 2022-12-13
Q2 2021 -$32.8M -$8.75M -$3.83M -77.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$29M -$13M -$3.61M -38.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$25.4M -$6.53M -$1.92M -41.5% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-03
Q3 2020 -$23.4M -$4.55M Jul 1, 2020 Sep 30, 2020 10-K 2021-11-18
Q2 2020 -$4.92M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$9.35M Jan 1, 2020 Mar 31, 2020 10-Q 2021-08-16
Q4 2019 -$4.61M Oct 1, 2019 Dec 31, 2019 10-Q 2021-08-16

ESSA Pharma Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$28.5M -$1.96M -7.38% Oct 1, 2023 Sep 30, 2024 10-K 2024-12-17
2023 -$26.6M +$8.52M +24.3% Oct 1, 2022 Sep 30, 2023 10-K 2024-12-17
2022 -$35.1M +$1.7M +4.63% Oct 1, 2021 Sep 30, 2022 10-K 2023-12-12
2021 -$36.8M -$13.4M -57% Oct 1, 2020 Sep 30, 2021 10-K 2022-12-13
2020 -$23.4M -$10.7M -83.8% Oct 1, 2019 Sep 30, 2020 10-K 2021-11-18
2019 -$12.8M Oct 1, 2018 Sep 30, 2019 10-K 2021-11-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.